- Home
- AIRI vs LPTX Comparison
AIRI vs LPTX Comparison
Compare AIRI & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- LPTX
- Stock Information
- Founded
- AIRI 1979
- LPTX 2011
- Country
- AIRI United States
- LPTX United States
- Employees
- AIRI N/A
- LPTX N/A
- Industry
- AIRI Military/Government/Technical
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRI Industrials
- LPTX Health Care
- Exchange
- AIRI Nasdaq
- LPTX Nasdaq
- Market Cap
- AIRI 13.4M
- LPTX 14.7M
- IPO Year
- AIRI N/A
- LPTX N/A
- Fundamental
- Price
- AIRI $3.33
- LPTX $0.31
- Analyst Decision
- AIRI
- LPTX Hold
- Analyst Count
- AIRI 0
- LPTX 1
- Target Price
- AIRI N/A
- LPTX N/A
- AVG Volume (30 Days)
- AIRI 100.8K
- LPTX 661.1K
- Earning Date
- AIRI 08-18-2025
- LPTX 08-19-2025
- Dividend Yield
- AIRI N/A
- LPTX N/A
- EPS Growth
- AIRI N/A
- LPTX N/A
- EPS
- AIRI N/A
- LPTX N/A
- Revenue
- AIRI $53,182,000.00
- LPTX N/A
- Revenue This Year
- AIRI N/A
- LPTX N/A
- Revenue Next Year
- AIRI $4.99
- LPTX N/A
- P/E Ratio
- AIRI N/A
- LPTX N/A
- Revenue Growth
- AIRI 0.29
- LPTX N/A
- 52 Week Low
- AIRI $3.00
- LPTX $0.22
- 52 Week High
- AIRI $9.44
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- AIRI 42.87
- LPTX 43.86
- Support Level
- AIRI $3.32
- LPTX $0.30
- Resistance Level
- AIRI $3.45
- LPTX $0.37
- Average True Range (ATR)
- AIRI 0.09
- LPTX 0.03
- MACD
- AIRI -0.02
- LPTX -0.00
- Stochastic Oscillator
- AIRI 12.00
- LPTX 28.53
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.